Rabeprazole Sodium Delayed Release Tablets

Modification P00003 SPE2D220D0096 has been issued to invoke option year 2 effective August 27, 2022 through August 26, 2023.

Modification P00002 SPE2D220D0096 has been issued to invoke option year 1 effective August 27, 2021 through August 26, 2022.

Modification P00001 SPE2D220D0096 to incorporate FAR 52.204-24 and FAR 52.204-25 into subject contract.

The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. Procurement details follow.

Rabeprazole Sodium DR 20MG in 30, 90 and 500 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual estimated usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.  

A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and FEDBIZOPS at https://www.fbo.gov. Interested parties should contact Phyllis Daraio (215-737-7941) email phyllis.daraio@dla.mil for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is February of 2020.  DLA reserves the right to issue the solicitation before or after the projected solicitation date.